Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00125-010-1951-1.

Title:
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study | Diabetologia
Description:
Fenofibrate caused an acute, sustained plasma creatinine increase in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies. We assessed fenofibrate’s renal effects overall and in a FIELD washout sub-study. Type 2 diabetic patients (n = 9,795) aged 50 to 75 years were randomly assigned to fenofibrate (n = 4,895) or placebo (n = 4,900) for 5 years, after 6 weeks fenofibrate run-in. Albuminuria (urinary albumin/creatinine ratio measured at baseline, year 2 and close-out) and estimated GFR, measured four to six monthly according to the Modification of Diet in Renal Disease Study, were pre-specified endpoints. Plasma creatinine was re-measured 8 weeks after treatment cessation at close-out (washout sub-study, n = 661). Analysis was by intention-to-treat. During fenofibrate run-in, plasma creatinine increased by 10.0 μmol/l (p < 0.001), but quickly reversed on placebo assignment. It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min−1 1.73 m−2 annually, p < 0.001). After washout, estimated GFR had fallen less from baseline on fenofibrate (1.9 ml min−1 1.73 m−2, p = 0.065) than on placebo (6.9 ml min−1 1.73 m−2, p < 0.001), sparing 5.0 ml min−1 1.73 m−2 (95% CI 2.3–7.7, p < 0.001). Greater preservation of estimated GFR with fenofibrate was observed with baseline hypertriacylglycerolaemia (n = 169 vs 491 without) alone, or combined with low HDL-cholesterol (n = 140 vs 520 without) and reductions of ≥0.48 mmol/l in triacylglycerol over the active run-in period (pre-randomisation) (n = 356 vs 303 without). Fenofibrate reduced urine albumin concentrations and hence albumin/creatinine ratio by 24% vs 11% (p < 0.001; mean difference 14% [95% CI 9–18]; p < 0.001), with 14% less progression and 18% more albuminuria regression (p < 0.001) than in participants on placebo. End-stage renal event frequency was similar (n = 21 vs 26, p = 0.48). Fenofibrate reduced albuminuria and slowed estimated GFR loss over 5 years, despite initially and reversibly increasing plasma creatinine. Fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients. Confirmatory studies are merited. ISRCTN64783481 The study was funded by grants from Laboratoires Fournier SA (Dijon, France; now part of Abbott Pharmaceuticals) and the National Health and Medical Research Council, Australia
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

fenofibrate, renal, creatinine, gfr, diabetes, estimated, study, plasma, article, patients, google, scholar, baseline, placebo, field, pubmed, cas, type, min, group, effects, acr, treatment, function, cardiovascular, disease, fig, albuminuria, urinary, participants, washout, years, greater, esm, rise, clinical, table, risk, diabetic, trial, substudy, runin, prespecified, μmoll, australia, kidney, glomerular, data, research, rate,

Topics {✒️}

peroxisome-proliferator-alpha receptor agonists revised sex-specific cut-points renin–angiotensin system blockers renin–angiotensin system blocker renin–angiotensin-system blocker renin–angiotensin system blockade end-stage renal disease angiotensin-converting enzyme inhibitor carotid intima-media thickness isotope-dilution mass spectrometry p-amino hippurate clearance fixed-dose combination therapies end-stage renal events low-density lipoprotein long-term fenofibrate therapy laser-requiring retinopathy occurred placebo-controlled clinical trials long-term fenofibrate treatment randomised placebo-controlled trial angiotensin-receptor blocker urinary albumin/creatinine ratio permanent renal injury full access chronic renal disease privacy choices/manage cookies chronic kidney disease underlying reno-protective mechanisms related subjects long-term reduction coronary heart disease longer term beneficial randomised controlled trial chronic underlying decline electronic supplementary material small sample size renal plasma flow study article published angiotensin ii antagonists clinical trials centre national heart foundation field placebo-treated patients physiology underlying plasminogen activating inhibitor-1 finnish diabetes association risk factors related reno-protection provided low hdl-cholesterol underlying renal preservation represent true nephrotoxicity glomerular filtration rate

Questions {❓}

  • Chudleigh RA, Dunseath G, Evans W et al (2007) How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes?
  • Heerspink HL, de Zeeuw D (2010) Composite renal endpoints: was ACCOMPLISH accomplished?
  • Is this a cause for concern?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
         description:Fenofibrate caused an acute, sustained plasma creatinine increase in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies. We assessed fenofibrate’s renal effects overall and in a FIELD washout sub-study. Type 2 diabetic patients (n = 9,795) aged 50 to 75 years were randomly assigned to fenofibrate (n = 4,895) or placebo (n = 4,900) for 5 years, after 6 weeks fenofibrate run-in. Albuminuria (urinary albumin/creatinine ratio measured at baseline, year 2 and close-out) and estimated GFR, measured four to six monthly according to the Modification of Diet in Renal Disease Study, were pre-specified endpoints. Plasma creatinine was re-measured 8 weeks after treatment cessation at close-out (washout sub-study, n = 661). Analysis was by intention-to-treat. During fenofibrate run-in, plasma creatinine increased by 10.0 μmol/l (p < 0.001), but quickly reversed on placebo assignment. It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min−1 1.73 m−2 annually, p < 0.001). After washout, estimated GFR had fallen less from baseline on fenofibrate (1.9 ml min−1 1.73 m−2, p = 0.065) than on placebo (6.9 ml min−1 1.73 m−2, p < 0.001), sparing 5.0 ml min−1 1.73 m−2 (95% CI 2.3–7.7, p < 0.001). Greater preservation of estimated GFR with fenofibrate was observed with baseline hypertriacylglycerolaemia (n = 169 vs 491 without) alone, or combined with low HDL-cholesterol (n = 140 vs 520 without) and reductions of ≥0.48 mmol/l in triacylglycerol over the active run-in period (pre-randomisation) (n = 356 vs 303 without). Fenofibrate reduced urine albumin concentrations and hence albumin/creatinine ratio by 24% vs 11% (p < 0.001; mean difference 14% [95% CI 9–18]; p < 0.001), with 14% less progression and 18% more albuminuria regression (p < 0.001) than in participants on placebo. End-stage renal event frequency was similar (n = 21 vs 26, p = 0.48). Fenofibrate reduced albuminuria and slowed estimated GFR loss over 5 years, despite initially and reversibly increasing plasma creatinine. Fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients. Confirmatory studies are merited. ISRCTN64783481 The study was funded by grants from Laboratoires Fournier SA (Dijon, France; now part of Abbott Pharmaceuticals) and the National Health and Medical Research Council, Australia
         datePublished:2010-11-04T00:00:00Z
         dateModified:2010-11-04T00:00:00Z
         pageStart:280
         pageEnd:290
         sameAs:https://doi.org/10.1007/s00125-010-1951-1
         keywords:
            Albuminuria
            Creatinine
            Diabetes
            Fenofibrate
            FIELD
            GFR
            Nephropathy
            Renal impairment
            Internal Medicine
            Metabolic Diseases
            Human Physiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig4_HTML.gif
         isPartOf:
            name:Diabetologia
            issn:
               1432-0428
               0012-186X
            volumeNumber:54
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:T. M. E. Davis
               affiliation:
                     name:University of Western Australia
                     address:
                        name:School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Ting
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
                     name:Royal Prince Alfred Hospital
                     address:
                        name:Royal Prince Alfred Hospital, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:J. D. Best
               affiliation:
                     name:University of Melbourne
                     address:
                        name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. W. Donoghoe
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. L. Drury
               affiliation:
                     name:Greenlane Clinical Centre
                     address:
                        name:Auckland Diabetes Centre, Greenlane Clinical Centre, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. R. Sullivan
               affiliation:
                     name:Royal Prince Alfred Hospital
                     address:
                        name:Royal Prince Alfred Hospital, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. J. Jenkins
               affiliation:
                     name:University of Melbourne
                     address:
                        name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. L. O’Connell
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. J. Whiting
               affiliation:
                     name:Flinders Medical Centre
                     address:
                        name:Flinders Medical Centre, Adelaide, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. P. Glasziou
               affiliation:
                     name:University of Oxford
                     address:
                        name:Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. J. Simes
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Y. A. Kesäniemi
               affiliation:
                     name:University of Oulu
                     address:
                        name:Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland
                        type:PostalAddress
                     type:Organization
                     name:University of Oulu
                     address:
                        name:Biocenter Oulu, University of Oulu, Oulu, Finland
                        type:PostalAddress
                     type:Organization
                     name:Oulu University Hospital
                     address:
                        name:Clinical Research Centre, Oulu University Hospital, Oulu, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:V. J. Gebski
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. S. Scott
               affiliation:
                     name:Christchurch Hospital
                     address:
                        name:Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. C. Keech
               affiliation:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                     address:
                        name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                        type:PostalAddress
                     type:Organization
                     name:Royal Prince Alfred Hospital
                     address:
                        name:Royal Prince Alfred Hospital, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
      description:Fenofibrate caused an acute, sustained plasma creatinine increase in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies. We assessed fenofibrate’s renal effects overall and in a FIELD washout sub-study. Type 2 diabetic patients (n = 9,795) aged 50 to 75 years were randomly assigned to fenofibrate (n = 4,895) or placebo (n = 4,900) for 5 years, after 6 weeks fenofibrate run-in. Albuminuria (urinary albumin/creatinine ratio measured at baseline, year 2 and close-out) and estimated GFR, measured four to six monthly according to the Modification of Diet in Renal Disease Study, were pre-specified endpoints. Plasma creatinine was re-measured 8 weeks after treatment cessation at close-out (washout sub-study, n = 661). Analysis was by intention-to-treat. During fenofibrate run-in, plasma creatinine increased by 10.0 μmol/l (p < 0.001), but quickly reversed on placebo assignment. It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min−1 1.73 m−2 annually, p < 0.001). After washout, estimated GFR had fallen less from baseline on fenofibrate (1.9 ml min−1 1.73 m−2, p = 0.065) than on placebo (6.9 ml min−1 1.73 m−2, p < 0.001), sparing 5.0 ml min−1 1.73 m−2 (95% CI 2.3–7.7, p < 0.001). Greater preservation of estimated GFR with fenofibrate was observed with baseline hypertriacylglycerolaemia (n = 169 vs 491 without) alone, or combined with low HDL-cholesterol (n = 140 vs 520 without) and reductions of ≥0.48 mmol/l in triacylglycerol over the active run-in period (pre-randomisation) (n = 356 vs 303 without). Fenofibrate reduced urine albumin concentrations and hence albumin/creatinine ratio by 24% vs 11% (p < 0.001; mean difference 14% [95% CI 9–18]; p < 0.001), with 14% less progression and 18% more albuminuria regression (p < 0.001) than in participants on placebo. End-stage renal event frequency was similar (n = 21 vs 26, p = 0.48). Fenofibrate reduced albuminuria and slowed estimated GFR loss over 5 years, despite initially and reversibly increasing plasma creatinine. Fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients. Confirmatory studies are merited. ISRCTN64783481 The study was funded by grants from Laboratoires Fournier SA (Dijon, France; now part of Abbott Pharmaceuticals) and the National Health and Medical Research Council, Australia
      datePublished:2010-11-04T00:00:00Z
      dateModified:2010-11-04T00:00:00Z
      pageStart:280
      pageEnd:290
      sameAs:https://doi.org/10.1007/s00125-010-1951-1
      keywords:
         Albuminuria
         Creatinine
         Diabetes
         Fenofibrate
         FIELD
         GFR
         Nephropathy
         Renal impairment
         Internal Medicine
         Metabolic Diseases
         Human Physiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-010-1951-1/MediaObjects/125_2010_1951_Fig4_HTML.gif
      isPartOf:
         name:Diabetologia
         issn:
            1432-0428
            0012-186X
         volumeNumber:54
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:T. M. E. Davis
            affiliation:
                  name:University of Western Australia
                  address:
                     name:School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Ting
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
                  name:Royal Prince Alfred Hospital
                  address:
                     name:Royal Prince Alfred Hospital, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:J. D. Best
            affiliation:
                  name:University of Melbourne
                  address:
                     name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. W. Donoghoe
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. L. Drury
            affiliation:
                  name:Greenlane Clinical Centre
                  address:
                     name:Auckland Diabetes Centre, Greenlane Clinical Centre, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. R. Sullivan
            affiliation:
                  name:Royal Prince Alfred Hospital
                  address:
                     name:Royal Prince Alfred Hospital, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. J. Jenkins
            affiliation:
                  name:University of Melbourne
                  address:
                     name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. L. O’Connell
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. J. Whiting
            affiliation:
                  name:Flinders Medical Centre
                  address:
                     name:Flinders Medical Centre, Adelaide, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. P. Glasziou
            affiliation:
                  name:University of Oxford
                  address:
                     name:Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. J. Simes
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Y. A. Kesäniemi
            affiliation:
                  name:University of Oulu
                  address:
                     name:Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland
                     type:PostalAddress
                  type:Organization
                  name:University of Oulu
                  address:
                     name:Biocenter Oulu, University of Oulu, Oulu, Finland
                     type:PostalAddress
                  type:Organization
                  name:Oulu University Hospital
                  address:
                     name:Clinical Research Centre, Oulu University Hospital, Oulu, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:V. J. Gebski
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. S. Scott
            affiliation:
                  name:Christchurch Hospital
                  address:
                     name:Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. C. Keech
            affiliation:
                  name:The FIELD Study, c/o NHMRC Clinical Trials Centre
                  address:
                     name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
                     type:PostalAddress
                  type:Organization
                  name:Royal Prince Alfred Hospital
                  address:
                     name:Royal Prince Alfred Hospital, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Diabetologia
      issn:
         1432-0428
         0012-186X
      volumeNumber:54
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Western Australia
      address:
         name:School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:Royal Prince Alfred Hospital
      address:
         name:Royal Prince Alfred Hospital, Sydney, Australia
         type:PostalAddress
      name:University of Melbourne
      address:
         name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:Greenlane Clinical Centre
      address:
         name:Auckland Diabetes Centre, Greenlane Clinical Centre, Auckland, New Zealand
         type:PostalAddress
      name:Royal Prince Alfred Hospital
      address:
         name:Royal Prince Alfred Hospital, Sydney, Australia
         type:PostalAddress
      name:University of Melbourne
      address:
         name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:Flinders Medical Centre
      address:
         name:Flinders Medical Centre, Adelaide, Australia
         type:PostalAddress
      name:University of Oxford
      address:
         name:Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:University of Oulu
      address:
         name:Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland
         type:PostalAddress
      name:University of Oulu
      address:
         name:Biocenter Oulu, University of Oulu, Oulu, Finland
         type:PostalAddress
      name:Oulu University Hospital
      address:
         name:Clinical Research Centre, Oulu University Hospital, Oulu, Finland
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:Christchurch Hospital
      address:
         name:Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
         type:PostalAddress
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre
      address:
         name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
         type:PostalAddress
      name:Royal Prince Alfred Hospital
      address:
         name:Royal Prince Alfred Hospital, Sydney, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:T. M. E. Davis
      affiliation:
            name:University of Western Australia
            address:
               name:School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
               type:PostalAddress
            type:Organization
      name:R. Ting
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
            name:Royal Prince Alfred Hospital
            address:
               name:Royal Prince Alfred Hospital, Sydney, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:J. D. Best
      affiliation:
            name:University of Melbourne
            address:
               name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
               type:PostalAddress
            type:Organization
      name:M. W. Donoghoe
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
      name:P. L. Drury
      affiliation:
            name:Greenlane Clinical Centre
            address:
               name:Auckland Diabetes Centre, Greenlane Clinical Centre, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      name:D. R. Sullivan
      affiliation:
            name:Royal Prince Alfred Hospital
            address:
               name:Royal Prince Alfred Hospital, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:A. J. Jenkins
      affiliation:
            name:University of Melbourne
            address:
               name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
               type:PostalAddress
            type:Organization
      name:R. L. O’Connell
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
      name:M. J. Whiting
      affiliation:
            name:Flinders Medical Centre
            address:
               name:Flinders Medical Centre, Adelaide, Australia
               type:PostalAddress
            type:Organization
      name:P. P. Glasziou
      affiliation:
            name:University of Oxford
            address:
               name:Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      name:R. J. Simes
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Y. A. Kesäniemi
      affiliation:
            name:University of Oulu
            address:
               name:Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland
               type:PostalAddress
            type:Organization
            name:University of Oulu
            address:
               name:Biocenter Oulu, University of Oulu, Oulu, Finland
               type:PostalAddress
            type:Organization
            name:Oulu University Hospital
            address:
               name:Clinical Research Centre, Oulu University Hospital, Oulu, Finland
               type:PostalAddress
            type:Organization
      name:V. J. Gebski
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
      name:R. S. Scott
      affiliation:
            name:Christchurch Hospital
            address:
               name:Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
               type:PostalAddress
            type:Organization
      name:A. C. Keech
      affiliation:
            name:The FIELD Study, c/o NHMRC Clinical Trials Centre
            address:
               name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
               type:PostalAddress
            type:Organization
            name:Royal Prince Alfred Hospital
            address:
               name:Royal Prince Alfred Hospital, Sydney, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, Australia
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Royal Prince Alfred Hospital, Sydney, Australia
      name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Auckland Diabetes Centre, Greenlane Clinical Centre, Auckland, New Zealand
      name:Royal Prince Alfred Hospital, Sydney, Australia
      name:Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Flinders Medical Centre, Adelaide, Australia
      name:Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland
      name:Biocenter Oulu, University of Oulu, Oulu, Finland
      name:Clinical Research Centre, Oulu University Hospital, Oulu, Finland
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
      name:The FIELD Study, c/o NHMRC Clinical Trials Centre, University of Sydney, Australia
      name:Royal Prince Alfred Hospital, Sydney, Australia

External Links {🔗}(180)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Isotope
  • Prism.js

CDN Services {📦}

  • Crossref

5.04s.